248 related articles for article (PubMed ID: 16956712)
21. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Yegnasubramanian S; Kowalski J; Gonzalgo ML; Zahurak M; Piantadosi S; Walsh PC; Bova GS; De Marzo AM; Isaacs WB; Nelson WG
Cancer Res; 2004 Mar; 64(6):1975-86. PubMed ID: 15026333
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?
Bernardini S; Miano R; Iori R; Finazzi-Agrò E; Palmieri G; Ballerini S; Angeloni C; Orlandi A; Bellincampi L; Cortese C; Federici G
Clin Chim Acta; 2004 Dec; 350(1-2):181-8. PubMed ID: 15530476
[TBL] [Abstract][Full Text] [Related]
23. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.
Bastian PJ; Yegnasubramanian S; Palapattu GS; Rogers CG; Lin X; De Marzo AM; Nelson WG
Eur Urol; 2004 Dec; 46(6):698-708. PubMed ID: 15548435
[TBL] [Abstract][Full Text] [Related]
24. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
Singal R; Ferdinand L; Reis IM; Schlesselman JJ
Oncol Rep; 2004 Sep; 12(3):631-7. PubMed ID: 15289848
[TBL] [Abstract][Full Text] [Related]
25. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
26. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Rogers CG; Lin X; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
J Urol; 2008 Feb; 179(2):529-34; discussion 534-5. PubMed ID: 18076941
[TBL] [Abstract][Full Text] [Related]
27. [Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma].
Yao Q; He XS; Zhang JM; He J
Zhonghua Nan Ke Xue; 2006 Jan; 12(1):28-31. PubMed ID: 16483154
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance.
Reibenwein J; Pils D; Horak P; Tomicek B; Goldner G; Worel N; Elandt K; Krainer M
Prostate; 2007 Mar; 67(4):427-32. PubMed ID: 17192910
[TBL] [Abstract][Full Text] [Related]
29. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators.
Ellinger J; Bastian PJ; Haan KI; Heukamp LC; Buettner R; Fimmers R; Mueller SC; von Ruecker A
Int J Cancer; 2008 Jan; 122(1):138-43. PubMed ID: 17764114
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma.
Lee HS; Kim BH; Cho NY; Yoo EJ; Choi M; Shin SH; Jang JJ; Suh KS; Kim YS; Kang GH
Clin Cancer Res; 2009 Feb; 15(3):812-20. PubMed ID: 19188151
[TBL] [Abstract][Full Text] [Related]
31. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
32. Methylated genes as potential biomarkers in prostate cancer.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
[TBL] [Abstract][Full Text] [Related]
33. Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Lou W; Krill D; Dhir R; Becich MJ; Dong JT; Frierson HF; Isaacs WB; Isaacs JT; Gao AC
Cancer Res; 1999 May; 59(10):2329-31. PubMed ID: 10344738
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
[TBL] [Abstract][Full Text] [Related]
35. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
36. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.
Rouprêt M; Hupertan V; Yates DR; Catto JW; Rehman I; Meuth M; Ricci S; Lacave R; Cancel-Tassin G; de la Taille A; Rozet F; Cathelineau X; Vallancien G; Hamdy FC; Cussenot O
Clin Cancer Res; 2007 Mar; 13(6):1720-5. PubMed ID: 17363525
[TBL] [Abstract][Full Text] [Related]
37. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
[TBL] [Abstract][Full Text] [Related]
38. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma.
Chu DC; Chuang CK; Fu JB; Huang HS; Tseng CP; Sun CF
J Urol; 2002 Apr; 167(4):1854-8. PubMed ID: 11912447
[TBL] [Abstract][Full Text] [Related]
39. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
40. [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma].
Liu WJ; Wang L; Wang JP; Li JQ; Zhang CQ; Zheng L; Yuan YF
Ai Zheng; 2006 Jun; 25(6):696-700. PubMed ID: 16764763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]